IMDX Submits GraftAssureDx for FDA Review and Reports Q4 2025 Results

Impact · against what's priced in

IMDX has reached a major value inflection point by submitting its GraftAssureDx assay for FDA review and demonstrating significant early market traction. While Bio-Rad's continued support is positive, the material catalyst is the transition of IMDX from a development-stage company to one with a clear path to a $2 billion addressable market.

IMDX+0.80

No priced-in read yet